.
MergerLinks Header Logo

Announced

Avalon Ventures and COI Pharmaceuticals sold Sitari Pharmaceuticals to GSK.

Financials

Edit Data
Transaction Value-
Consideration TypeCash
Capital Owned-
Capital Bid For100%
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

celiac disease treatment

Acquisition

Friendly

Pending

Medical Services

Private Equity

Single Bidder

United States

Private

Synopsis

Edit

Avalon Ventures and COI Pharmaceuticals sold Sitari Pharmaceuticals, a developer of a novel treatment for celiac disease, to GlaxoSmithKline, a British multinational pharmaceutical company. Financial terms were not disclosed. “Over the last six years, GSK and Avalon have pioneered a unique biotech funding model designed to identify novel targets from top-tier academic labs and translate cutting-edge discoveries into promising clinical candidates,” said John Lepore, SVP, Research, GSK. “Bringing the Sitari TG2 program into GSK is strongly aligned with our research focus on genetically-associated targets and immune-driven disease. The current standard of care for celiac disease is strict adherence to a gluten-free diet, but a significant number of patients still experience gastrointestinal symptoms and disease progression. TG2 inhibition could represent a new hope for celiac disease patients.”

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US